Correction to: Journal of Neuro-Oncology (2019) 142:211–221 https://doi.org/10.1007/s11060-019-03104-3
Issues with data analysis have recently been highlighted by a reader of our article. These have been addressed with changes to Tables 2 and 4, as shown below, and Online Resources 5–7. T2 and peritumoral signal are no longer prognostic factors on simple pooled (Online Resource 5) and IPD (Table 4) analyses respectively. In Table 5, the number of patients which informed the outcomes symptom development and intervention were 575 and 947 respectively; 69 developed symptoms (pooled proportion %8.4 [95% CI 2.8–16.7], I2 = 88.9%). These included motor and cognitive deficits (n = 1). We apologise to the readership of the Journal of Neuro-Oncology for these errors and thank the reader for helping us identify them.
Table 2
Baseline clinical and radiological characteristics
No. of studies informing characteristic | No. of valid cases informing characteristic (%) | Characteristics | Total | Surgery | SRS | Active monitoring | P | |
|---|---|---|---|---|---|---|---|---|
18 | 2050 | N. of patients (%) | 2050 | 560 (27.3) | 450 (22.0) | 1040 (50.7) | ||
13 | 803 (39.2) | Mean age, years (SD) | 63.1 (6.9) | 61.5 (4.7) | 54.9 (NR)b | 64 (6.9) | < 0.001 | |
17 | 1948 (95.0) | Sex, N (%) | Female | 1549 | 369 (23.8) | 363 (23.4) | 817 (52.7) | 0.539 |
Male | 399 | 89 (22.3) | 87 (21.8) | 223 (55.9) | ||||
16 | 1495 (72.9) | Location, N (%)a | Non-skull base | 1024 | 277 (27.1) | 235 (22.9) | 512 (50.0) | < 0.001 |
Convexity | 431 | 126 | 86 | 219 | ||||
Parafalcine | 245 | 61 | 71 | 113 | ||||
Parasagittal | 151 | 42 | 36 | 73 | ||||
Tentorial | 62 | 12 | 28 | 22 | ||||
Intraventricular | 26 | 4 | 12 | 10 | ||||
Skull base | 471 | 106 (22.5) | 154 (32.7) | 211 (44.8) | ||||
Anterior midline | 112 | 22 | 43 | 47 | ||||
Sphenoid wing | 98 | 25 | 11 | 62 | ||||
Posterior fossa - lateral and posterior | 52 | 23 | 12 | 17 | ||||
Posterior fossa - midline | 138 | 17 | 87 | 34 | ||||
15 | 888 (43.3) | Mean diameter, cm (SD) | 2.14 (0.61) | 2.11 (0.42) | 1.73 (NR)b | 2.19 (0.66) | <0.001 | |
10 | 615 (30.0) | Calcification, N (%) | No | 394 | 64 (16.2) | NR | 330 (83.8) | 0.177 |
Yes | 221 | 27 (12.2) | NR | 194 (87.8) | ||||
5 | 298 (14.5) | Tumor signal intensity, N (%) | Hyperintense | 120 | 40 (33.3) | NR | 80 (66.6) | 0.237 |
Iso/hypointense | 178 | 48 (27.0) | NR | 130 (73.0) | ||||
12 | 1107 (54.0) | Peritumoral edema, N (%) | Yes | 144 | 47 (32.6) | 24 (16.7) | 73 (50.7) | |
No | 963 | 145 (15.1) | 365 (37.9) | 453 (47.0) |
Table 4
Growth dynamics and symptom development during active monitoring stratified by baseline characteristics
Factor | Mean/median AGR (cm3/year) | P | Mean/median RGR (%/year) | P | Symptom development, yes/total (%) | OR (95% CI) | MLR Pa | |
|---|---|---|---|---|---|---|---|---|
Location | Non-skull base | 7.97/0.68 | 0.747 | 70.2/17.0 | 0.405 | 12/60 (20.0) | 0.116 | |
Skull base | 5.82/2.93 | 28.1/17.2 | 5/25 (20.0) | |||||
Diameter | ≥ 3.0 cm | 19.7/5.91 | 0.004 | 114/24.7 | 0.091 | 15/27 (55.5) | 12.16 (5.56–18.78) | < 0.001 |
< 3.0 cm | 1.56/0.46 | 31.4/12.7 | 2/58 (3.45) | |||||
Calcification | No | 19.0/19.0 | NA | 141/141 | NA | 1/1 (100) | ||
Yes | NR | NR | NR | |||||
Tumor signal intensity | Hyperintense | NR | NA | NR | NA | NR | ||
Iso/hypointense | NR | NR | NR | |||||
Peritumoral edema | Yes | NR | NA | NR | NA | NR | ||
No | 2.32/0.62 | 19.7/13.2 | 1/29 (3.45) |
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.